Novartis expands development programs for NASH through clinical collaboration with Allergan - Seite 3
Disclaimer
The foregoing release contains forward-looking statements that can be identified by words such as "expands," "development programs," "to evaluate," "rapidly growing," "investigating," "to
investigate," "positive change," "believe," "Fast Track designation," "investigational," "will," "option," "growing," "potential," "may," "expected," or similar terms, or by express or implied
discussions regarding potential marketing approvals for cenicriviroc, the FXR agonists being developed internally by Novartis, and emricasan, either as single agents or in combination, or regarding
potential future revenues from these products. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of
management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the necessary government approvals for the
transaction with Allergan or exercise of the option with Conatus will be obtained in any particular time frame, or at all. Neither can there be any guarantee that any other closing conditions for
the transactions with Allergan or Conatus will be met in any particular time frame, or at all. Nor can there be any guarantee that the collaborations with Allergan or Conatus will achieve any of
their intended goals and objectives, or in any particular time frame. Nor can there be any guarantee that cenicriviroc or the FXR agonists being developed internally by Novartis, or emricaasan,
either as single agents or in combination, will be submitted or approved for sale in any market, or at any particular time. Nor can there be any guarantee that any or all of these products will be
commercially successful in the future. Management's expectations regarding each of the transactions, cenicriviroc, emricasan, and the FXR agonists being developed internally by Novartis could be
affected by, among other things, a failure to obtain necessary government approvals for the transactions with Allergan and Conatus, or delays in obtaining such approvals, and the potential that any
other closing conditions for the transaction may not be met; the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical
data; regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain proprietary intellectual property protection; general economic and industry
conditions; global trends toward health care cost containment, including ongoing pricing pressures; safety, quality or manufacturing issues, and other risks and factors referred to in Novartis AG's
current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update
any forward-looking statements contained in this press release as a result of new information, future events or otherwise.